… PROTAC technology to generate a cell-selective BCL-X L … The potent antitumor activity of
DT2216 was correlated with its … that DT2216 is a safer and more potent antitumor agent than …

… the utility of PROTAC technology to achieve tissue … activity. Compound 17b (XZ739), which
contains a PEG linker with linker length of 11 atoms, was the most potent BCL-X L degrader …

… , a potent VHL-based BCL-xL PROTAC, as a safer and more potent antitumor agent than its
… are located within the band region which is feasible to achieve a conformation that is close to …

… Thus, we have demonstrated that the PROTAC technology could be used to achieve tissue/cell
selectivity by targeting E3 ligases that are differentially expressed in different tissues/cells…

… versus inhibition, (18−20) we report the design of a chemically distinct Bcl-xL VHL degrader,
… ternary complexation to achieve selective degradation of Bcl-xL over Bcl-2, PROTAC 6 may …

… -225, pediatric patients whose bones have not achieved full maturity were found to develop
… Furthermore, we found that the potent antitumor activity of SIAIS316034 corresponded well …

… Unlike conventional SMIs, the PROTAC molecule can be … To achieve positive cooperatively
in PROTAC strategy, the … was selectively Bcl-x L degrader but not a Bcl-2 degrader. …

… importance of selecting suitable E3 members to achieve effective cellular activity. … degrade
BCL-X L and kill various cancer cells [[14], [15], [16]]. PROTAC 8a has similar cell killing effect …

… of Bcl-xl could confer can cells resistance against BET inhibitors [5], we hypothesized that
Bcl-xl PROTAC, when combined with BET inhibitors, may increase their anti-tumor effects. To …

… (PROTAC) targeting Bcl-xL for degradation via Von Hippel-Lindau (VHL) E3 ligase, and
shown that it has better anti-tumor activity … cannot be achieved by the use of either Bcl-xl-specific …